Kenvue

Kenvue

Kenvue launched as an independent public company in May 2023, completing Johnson & Johnson's multi-year plan to disentangle its slower-growing consumer division from faster-growth pharmaceuticals and medical devices. Thibaut Mongon, a two-decade J&J veteran, became CEO, leading a carve-out that generated approximately $15 billion in annual revenue at separation. The entity inherited J&J's entire consumer-health portfolio, a collection of brands spanning self-care, skin health, and essential wellness with household penetration across more than 165 countries. The company operates three core segments: Self Care, Skin Health & Beauty, and Essential Health. Self Care includes analgesics like Tylenol and Motrin, upper-respiratory treatments such as Zyrtec and Benadryl, and smoking-cessation aids like Nicorette. Skin Health & Beauty houses Neutrogena, Aveeno, and OGX, competing in mass-market dermocosmetics. Essential Health covers wound care (Band-Aid), oral care (Listerine), baby care (Johnson's), and feminine hygiene. Geographically, North America generates roughly half of revenue, with the remainder split across Europe, Asia-Pacific, and Latin America. Kenvue deploys capital into brand marketing, supply-chain optimization, and portfolio rationalization rather than venture-style investing — it has sold non-core assets like the Dr. Ci:Labo business in Japan (per Reuters, 2023). Kenvue maintains dual headquarters in Skillman, New Jersey and Zug, Switzerland, and employs over 22,000 people across its operating footprint. Its public listing on the New York Stock Exchange under ticker KVUE initially raised $3.8 billion in the IPO, with J&J retaining a roughly 90% stake before exchanging the shares for debt in an August 2023 split-off that fully separated the entities (per the firm, 2023). The company has a straightforward public-equity structure with no adjacent family office, philanthropic foundation, or co-investment club. In the year following independence, Kenvue focused on restructuring its supply chain and increasing digital advertising spending to combat private-label competition. Kenvue's structural distinction lies in its clean, single-line-of-business public-company architecture. Unlike diversified healthcare conglomerates that spread capital allocation across drug pipelines, medtech acquisition targets, and consumer brands simultaneously, Kenvue is a pure-play consumer-health entity that can reinvest all operating cash flow directly into brand building, shelf-space defense, and targeted category acquisitions. The governance now rests with an independent board, without the internal capital-market competition against higher-return pharmaceutical divisions that constrained the business inside J&J.